{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:46:13Z","timestamp":1785786373368,"version":"3.56.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI146241"],"award-info":[{"award-number":["R01AI146241"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI170889"],"award-info":[{"award-number":["R01AI170889"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40121-025-01215-1","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T17:12:10Z","timestamp":1756919530000},"page":"2221-2246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?"],"prefix":"10.1007","volume":"14","author":[{"given":"Maytham","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuezhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha J.","family":"Thombare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya B.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajnikant","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri G.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A. T.","family":"Blaskovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Velkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"issue":"4","key":"1215_CR1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41579-018-0147-4","volume":"17","author":"NA Turner","year":"2019","unstructured":"Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019;17(4):203\u201318.","journal-title":"Nat Rev Microbiol"},{"key":"1215_CR2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-060614-034516","volume":"84","author":"SJ Peacock","year":"2015","unstructured":"Peacock SJ, Paterson GK. Mechanisms of methicillin resistance in Staphylococcus aureus. Annu Rev Biochem. 2015;84:577\u2013601.","journal-title":"Annu Rev Biochem"},{"key":"1215_CR3","unstructured":"CDC. The biggest antibiotic-resistant threats in the U.S: US. Centers for Disease Control and Prevention. 2019. https:\/\/www.cdc.gov\/drugresistance\/biggest_threats.html. Accessed 16 Apr 2025."},{"key":"1215_CR4","unstructured":"World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2024. Geneva: World Health Organization; 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240093461. Accessed 16 Apr 2025."},{"issue":"3","key":"1215_CR5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/SMJ.0b013e3181647037","volume":"101","author":"DP Levine","year":"2008","unstructured":"Levine DP. Vancomycin: understanding its past and preserving its future. South Med J. 2008;101(3):284\u201391.","journal-title":"South Med J"},{"issue":"5","key":"1215_CR6","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1016\/S1074-5521(00)00116-2","volume":"7","author":"VL Healy","year":"2000","unstructured":"Healy VL, Lessard IAD, Roper DI, Knox JR, Walsh CT. Vancomycin resistance in enterococci: reprogramming of the d-Ala\u2013d-Ala ligases in bacterial peptidoglycan biosynthesis. Chem Biol. 2000;7(5):R109\u201319.","journal-title":"Chem Biol"},{"issue":"5","key":"1215_CR7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jcpt.12743","volume":"43","author":"PO Lewis","year":"2018","unstructured":"Lewis PO, Heil EL, Covert KL, Cluck DB. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther. 2018;43(5):614\u201325.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"1215_CR8","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2215\/CJN.11011016","volume":"11","author":"TD Nolin","year":"2016","unstructured":"Nolin TD. Vancomycin and the risk of AKI: now clearer than Mississippi mud. Clin J Am Soc Nephrol. 2016;11(12):2101\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Pt 2","key":"1215_CR9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1107\/S2052252524000289","volume":"11","author":"JH Park","year":"2024","unstructured":"Park JH, Reviello RE, Loll PJ. Crystal structure of vancomycin bound to the resistance determinant D-alanine-D-serine. IUCrJ. 2024;11(Pt 2):133\u20139.","journal-title":"IUCrJ"},{"issue":"2","key":"1215_CR10","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.47.2.568-576.2003","volume":"47","author":"A Reipert","year":"2003","unstructured":"Reipert A, Ehlert K, Kast T, Bierbaum G. Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicrob Agents Chemother. 2003;47(2):568\u201376.","journal-title":"Antimicrob Agents Chemother"},{"key":"1215_CR11","doi-asserted-by":"crossref","first-page":"1158152","DOI":"10.3389\/fphar.2023.1158152","volume":"14","author":"AJJ Koh","year":"2023","unstructured":"Koh AJJ, Thombare V, Hussein M, Rao GG, Li J, Velkov T. Bifunctional antibiotic hybrids: a review of clinical candidates. Front Pharmacol. 2023;14:1158152.","journal-title":"Front Pharmacol"},{"issue":"18","key":"1215_CR12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","volume":"75","author":"F Van Bambeke","year":"2015","unstructured":"Van Bambeke F. Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review. Drugs. 2015;75(18):2073\u201395.","journal-title":"Drugs"},{"key":"1215_CR13","doi-asserted-by":"publisher","DOI":"10.1099\/mgen.0.000283","author":"C Gorrie","year":"2019","unstructured":"Gorrie C, Higgs C, Carter G, Stinear TP, Howden B. Genomics of vancomycin-resistant Enterococcus faecium. Microb Genom. 2019. https:\/\/doi.org\/10.1099\/mgen.0.000283.","journal-title":"Microb Genom"},{"issue":"Supplement_3","key":"1215_CR14","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/ciz004","volume":"68","author":"Y Golan","year":"2019","unstructured":"Golan Y. Current treatment options for acute skin and skin-structure infections. Clin Infect Dis. 2019;68(Supplement_3):S206\u201312.","journal-title":"Clin Infect Dis"},{"key":"1215_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00579-4","author":"M D\u00edaz-Navarro","year":"2022","unstructured":"D\u00edaz-Navarro M, Hafian R, Manzano I, et al. A dalbavancin lock solution can reduce enterococcal biofilms after freezing. Infect Dis Ther. 2022. https:\/\/doi.org\/10.1007\/s40121-021-00579-4.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1215_CR16","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/life13040959","volume":"13","author":"T Lupia","year":"2023","unstructured":"Lupia T, De Benedetto I, Bosio R, Shbaklo N, De Rosa FG, Corcione S. Role of oritavancin in the treatment of infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans: narrative review and possible developments. Life. 2023;13(4):959.","journal-title":"Life"},{"issue":"4","key":"1215_CR17","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s15010-024-02176-2","volume":"52","author":"S Esposito","year":"2024","unstructured":"Esposito S, Pagliano P, De Simone G, et al. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a national registry. Infection. 2024;52(4):1297\u2013306.","journal-title":"Infection"},{"issue":"3","key":"1215_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","volume":"4","author":"JR Smith","year":"2015","unstructured":"Smith JR, Roberts KD, Rybak MJ. Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther. 2015;4(3):245\u201358.","journal-title":"Infect Dis Ther"},{"key":"1215_CR19","unstructured":"FDA. Dalbavancin (FDA Label). 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021883s010lbl.pdf. Accessed 16 Apr 2025."},{"key":"1215_CR20","unstructured":"FDA. Oritavancin (FDA Label). 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206334s006lbl.pdf. Accessed 16 Apr 2025."},{"issue":"4","key":"1215_CR21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkx473","volume":"73","author":"CJ Byrne","year":"2017","unstructured":"Byrne CJ, Parton T, McWhinney B, et al. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J Antimicrob Chemother. 2017;73(4):995\u20131003.","journal-title":"J Antimicrob Chemother"},{"key":"1215_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0213-005X(17)30029-0","volume":"35","author":"E Cercenado","year":"2017","unstructured":"Cercenado E. Espectro antimicrobiano de dalbavancina. Mecanismo de acci\u00f3n y actividad in vitro frente a microorganismos Gram positivos. Enferm Infecc Microbiol Clin. 2017;35:9\u201314.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"2","key":"1215_CR23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diagmicrobio.2004.06.007","volume":"50","author":"SM Bhavnani","year":"2004","unstructured":"Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004;50(2):95\u2013102.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"1215_CR24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.annemergmed.2009.03.014","volume":"55","author":"M Duong","year":"2010","unstructured":"Duong M, Markwell S, Peter J, Barenkamp S. Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med. 2010;55(5):401\u20137.","journal-title":"Ann Emerg Med"},{"issue":"9","key":"1215_CR25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","volume":"67","author":"MS Butler","year":"2014","unstructured":"Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo). 2014;67(9):631\u201344.","journal-title":"J Antibiot (Tokyo)"},{"issue":"5","key":"1215_CR26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","volume":"61","author":"AY Chen","year":"2007","unstructured":"Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract. 2007;61(5):853\u201363.","journal-title":"Int J Clin Pract"},{"issue":"13","key":"1215_CR27","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","volume":"16","author":"S Ramdeen","year":"2015","unstructured":"Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015;16(13):2073\u201381.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"1215_CR28","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","volume":"37","author":"E Seltzer","year":"2003","unstructured":"Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37(10):1298\u2013303.","journal-title":"Clin Infect Dis"},{"issue":"23","key":"1215_CR29","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169\u201379.","journal-title":"N Engl J Med"},{"key":"1215_CR30","unstructured":"Barrett JF. Oritavancin. Eli Lilly & Co. Curr Opin Investig Drugs. 2001;2(8):1039\u201344."},{"issue":"6","key":"1215_CR31","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.47.6.1907-1911.2003","volume":"47","author":"C Cabellos","year":"2003","unstructured":"Cabellos C, Fern\u00e0ndez A, Maiques JM, et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 2003;47(6):1907\u201311.","journal-title":"Antimicrob Agents Chemother"},{"issue":"50","key":"1215_CR32","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.1021\/ja964477f","volume":"119","author":"GJ Sharman","year":"1997","unstructured":"Sharman GJ, Try AC, Dancer RJ, et al. The roles of dimerization and membrane anchoring in activity of glycopeptide antibiotics against vancomycin-resistant bacteria. J Am Chem Soc. 1997;119(50):12041\u20137.","journal-title":"J Am Chem Soc"},{"key":"1215_CR33","unstructured":"Arena CT. Oritavancin \u2013 glycopeptide antibiotic. Oritavancin is an investigational glycopeptide antibiotic being developed by Targanta Therapeutics for the treatment of: Clinical Trials Arena; 2008. https:\/\/www.clinicaltrialsarena.com\/marketdata\/oritavancin\/. Accessed 16 Apr 2025."},{"key":"1215_CR34","unstructured":"NEJM Journal Watch. FDA approves oritavancin for skin infections. 2014. https:\/\/www.jwatch.org\/na35529\/2014\/08\/26\/fda-approves-oritavancin-skin-infections. Accessed 16 Apr 2025."},{"key":"1215_CR35","first-page":"225","volume":"12","author":"JJ Juul","year":"2016","unstructured":"Juul JJ, Mullins CF, Peppard WJ, Huang AM. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin. Ther Clin Risk Manag. 2016;12:225\u201332.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"1215_CR36","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/13543784.16.5.717","volume":"16","author":"A Kim","year":"2007","unstructured":"Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs. 2007;16(5):717\u201333.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1215_CR37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/acsinfecdis.7b00258","volume":"4","author":"MAT Blaskovich","year":"2018","unstructured":"Blaskovich MAT, Hansford KA, Butler MS, Jia Z, Mark AE, Cooper MA. Developments in glycopeptide antibiotics. ACS Infect Dis. 2018;4(5):715\u201335.","journal-title":"ACS Infect Dis"},{"issue":"Suppl 2","key":"1215_CR38","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/jac\/dki005","volume":"55","author":"A Malabarba","year":"2005","unstructured":"Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl 2):ii15-20.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1215_CR39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2146\/ajhp070255","volume":"65","author":"J Bailey","year":"2008","unstructured":"Bailey J, Summers KM. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health-Syst Pharm. 2008;65(7):599\u2013610.","journal-title":"Am J Health-Syst Pharm"},{"issue":"16","key":"1215_CR40","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1039\/C3OB42428F","volume":"12","author":"M Cheng","year":"2014","unstructured":"Cheng M, Ziora ZM, Hansford KA, Blaskovich MA, Butler MS, Cooper MA. Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin. Org Biomol Chem. 2014;12(16):2568\u201375.","journal-title":"Org Biomol Chem"},{"issue":"1","key":"1215_CR41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/jcpt.12580","volume":"43","author":"JM Steele","year":"2018","unstructured":"Steele JM, Seabury RW, Hale CM, Mogle BT. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. J Clin Pharm Ther. 2018;43(1):101\u20133.","journal-title":"J Clin Pharm Ther"},{"key":"1215_CR42","unstructured":"Biondi S, Chugunova E, Panunzio M. Chapter 8 - From natural products to drugs: glyco- and lipoglycopeptides, a new generation of potent cell wall biosynthesis inhibitors. In: Rahman A ur, editor. Studies in natural products chemistry, vol. 50. Amsterdam: Elsevier; 2016. p. 249\u201397."},{"issue":"5","key":"1215_CR43","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1574-6976.2003.tb00628.x","volume":"26","author":"NE Allen","year":"2003","unstructured":"Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 2003;26(5):511\u201332.","journal-title":"FEMS Microbiol Rev"},{"issue":"6","key":"1215_CR44","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkp126","volume":"63","author":"GA McKay","year":"2009","unstructured":"McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother. 2009;63(6):1191\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1215_CR45","unstructured":"Barrett J. Oritavancin. Eli Lilly & Co. Curr Opin Investig Drugs. 2001;2(8):1039\u201344."},{"issue":"12","key":"1215_CR46","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/AAC.00760-10","volume":"54","author":"A Belley","year":"2010","unstructured":"Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother. 2010;54(12):5369\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"1215_CR47","unstructured":"FDA. Dalbavancin label, highlights of prescribing information: Food and Drug Administration. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021883s007lbl.pdf. Accessed 16 Apr 2025."},{"key":"1215_CR48","doi-asserted-by":"crossref","unstructured":"Koeth LM, DiFranco-Fisher JM, McCurdy S. A reference broth microdilution method for dalbavancin in vitro susceptibility testing of bacteria that grow aerobically. J Vis Exp. 2015;(103):53028.","DOI":"10.3791\/53028-v"},{"issue":"10","key":"1215_CR49","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1128\/JCM.02411-06","volume":"45","author":"RP Rennie","year":"2007","unstructured":"Rennie RP, Koeth L, Jones RN, et al. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol. 2007;45(10):3151\u20134.","journal-title":"J Clin Microbiol"},{"key":"1215_CR50","unstructured":"Research CfDEa. Division of Anti-infective Products. Dalbavancin, Durata Therapeutics. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/021883Orig1s000MicroR.pdf. Accessed 16 Apr 2025."},{"issue":"7","key":"1215_CR51","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","volume":"70","author":"GG Zhanel","year":"2010","unstructured":"Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859\u201386.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"1215_CR52","doi-asserted-by":"crossref","first-page":"ii21","DOI":"10.1093\/jac\/dki007","volume":"55","author":"S Lopez","year":"2005","unstructured":"Lopez S, Hackbarth C, Romano G, Trias J, Jabes D, Goldstein BP. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii21\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1215_CR53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijantimicag.2010.06.044","volume":"36","author":"F Campanile","year":"2010","unstructured":"Campanile F, Borbone S, Perez M, et al. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int J Antimicrob Agents. 2010;36(5):415\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"16","key":"1215_CR54","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.1073\/pnas.150116497","volume":"97","author":"DI Roper","year":"2000","unstructured":"Roper DI, Huyton T, Vagin A, Dodson G. The molecular basis of vancomycin resistance in clinically relevant Enterococci: crystal structure of D-alanyl-D-lactate ligase (VanA). Proc Natl Acad Sci U S A. 2000;97(16):8921\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1215_CR55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1586\/14787210.6.1.67","volume":"6","author":"GG Zhanel","year":"2008","unstructured":"Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections. Expert Rev Anti-Infect Ther. 2008;6(1):67\u201381.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"3","key":"1215_CR56","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkac434","volume":"78","author":"J Al Janabi","year":"2023","unstructured":"Al Janabi J, Tevell S, Sieber RN, Stegger M, S\u00f6derquist B. Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections. J Antimicrob Chemother. 2023;78(3):669\u201377.","journal-title":"J Antimicrob Chemother"},{"key":"1215_CR57","doi-asserted-by":"crossref","unstructured":"Werth BJ, Jain R, Hahn A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018;24(4):429.e1\u2013e5.","DOI":"10.1016\/j.cmi.2017.07.028"},{"key":"1215_CR58","doi-asserted-by":"crossref","unstructured":"\u017diemyt\u0117 M, Rodr\u00edguez-D\u00edaz JC, Ventero MP, Mira A, Ferrer MD. Effect of dalbavancin on staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds. Front Microbiol. 2020;11:553.","DOI":"10.3389\/fmicb.2020.00553"},{"issue":"5","key":"1215_CR59","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2018.07.012","volume":"52","author":"Q Yan","year":"2018","unstructured":"Yan Q, Karau MJ, Raval YS, Patel R. In vitro activity of oritavancin in combination with rifampin or gentamicin against prosthetic joint infection-associated methicillin-resistant Staphylococcus epidermidis biofilms. Int J Antimicrob Agents. 2018;52(5):608\u201315.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"1215_CR60","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/1120009X.2018.1516272","volume":"30","author":"RE Mendes","year":"2018","unstructured":"Mendes RE, Sader HS, Castanheira M, Flamm RK. Distribution of main gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY antimicrobial surveillance program (2010\u20132016): concomitant analysis of oritavancin in vitro activity. J Chemother. 2018;30(5):280\u20139.","journal-title":"J Chemother"},{"issue":"11","key":"1215_CR61","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1128\/AAC.00952-09","volume":"53","author":"FF Arhin","year":"2009","unstructured":"Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother. 2009;53(11):4762\u201371.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1215_CR62","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1128\/AAC.01513-07","volume":"52","author":"FF Arhin","year":"2008","unstructured":"Arhin FF, Sarmiento I, Belley A, et al. Effect of polysorbate\u00a080 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008;52(5):1597\u2013603.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1215_CR63","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01760-18","volume":"63","author":"A Kavanagh","year":"2019","unstructured":"Kavanagh A, Ramu S, Gong Y, Cooper MA, Blaskovich MAT. Effects of microplate type and broth additives on microdilution MIC susceptibility assays. Antimicrob Agents Chemother. 2019;63(1): 10.1128\/aac.01760-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1215_CR64","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijantimicag.2015.08.014","volume":"46","author":"DJ Biedenbach","year":"2015","unstructured":"Biedenbach DJ, Arhin FF, Moeck G, Lynch TF, Sahm DF. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011\u20132014. Int J Antimicrob Agents. 2015;46(6):674\u201381.","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"1215_CR65","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1128\/AAC.00169-16","volume":"60","author":"A Belley","year":"2016","unstructured":"Belley A, Lalonde Seguin D, Arhin F, Moeck G. Comparative in vitro activities of oritavancin, dalbavancin, and vancomycin against methicillin-resistant Staphylococcus aureus isolates in a nondividing state. Antimicrob Agents Chemother. 2016;60(7):4342\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"1215_CR66","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1128\/AAC.48.12.4762-4765.2004","volume":"48","author":"B Bozdogan","year":"2004","unstructured":"Bozdogan B, Ednie L, Credito K, Kosowska K, Appelbaum PC. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother. 2004;48(12):4762\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"1215_CR67","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.43.8.1875","volume":"43","author":"M Arthur","year":"1999","unstructured":"Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother. 1999;43(8):1875\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1215_CR68","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.idc.2020.08.004","volume":"34","author":"WR Miller","year":"2020","unstructured":"Miller WR, Murray BE, Rice LB, Arias CA. Resistance in vancomycin-resistant enterococci. Infect Dis Clin North Am. 2020;34(4):751\u201371.","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"1215_CR69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diagmicrobio.2018.05.010","volume":"92","author":"Q Yan","year":"2018","unstructured":"Yan Q, Karau MJ, Patel R. In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection. Diagn Microbiol Infect Dis. 2018;92(2):155\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"1215_CR70","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jac\/dkl311","volume":"58","author":"KE Bowker","year":"2006","unstructured":"Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother. 2006;58(4):802\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1215_CR71","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/17425255.2018.1420162","volume":"14","author":"M Galluzzo","year":"2018","unstructured":"Galluzzo M, D\u2019Adamio S, Bianchi L, Talamonti M. Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. Expert Opin Drug Metab Toxicol. 2018;14(2):197\u2013206.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"1215_CR72","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1215_CR73","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0091270008321273","volume":"48","author":"JA Dowell","year":"2008","unstructured":"Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol. 2008;48(9):1063\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1215_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.695","author":"TJ Carrothers","year":"2019","unstructured":"Carrothers TJ, Chittenden JT, Critchley I. Dalbavancin population pharmacokinetic modeling and target attainment analysis. Clin Pharmacol Drug Dev. 2019. https:\/\/doi.org\/10.1002\/cpdd.695.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1215_CR75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40265-016-0666-0","volume":"77","author":"KP Garnock-Jones","year":"2017","unstructured":"Garnock-Jones KP. Single-dose dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2017;77(1):75\u201383.","journal-title":"Drugs"},{"issue":"3","key":"1215_CR76","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/jac\/dkm263","volume":"60","author":"DP Nicolau","year":"2007","unstructured":"Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother. 2007;60(3):681\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1215_CR77","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59(4):1849\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"1215_CR78","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0213-005X(17)30031-9","volume":"35","author":"JR Azanza","year":"2017","unstructured":"Azanza JR, S\u00e1daba B, Reis J. Dalbavancin: pharmacokinetic and pharmacodynamic parameters. Enferm Infecc Microbiol Clin. 2017;35(Suppl 1):22\u20137.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"1215_CR79","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01024-19","author":"U Rappo","year":"2019","unstructured":"Rappo U, Dunne MW, Puttagunta S, et al. Epithelial lining fluid and plasma concentrations of dalbavancin in healthy adults after a single 1,500-milligram infusion. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.01024-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1215_CR80","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/jpp.JPP_2_17","volume":"8","author":"KE Barber","year":"2017","unstructured":"Barber KE, Tirmizi A, Finley R, Stover KR. Dalbavancin use for the treatment of methicillin-resistant Staphylococcus aureus pneumonia. J Pharmacol Pharmacother. 2017;8(2):77\u20139.","journal-title":"J Pharmacol Pharmacother"},{"issue":"9","key":"1215_CR81","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1310\/hpj4909-851","volume":"49","author":"DJ Cada","year":"2014","unstructured":"Cada DJ, Ingram K, Baker DE. Dalbavancin. Hosp Pharm. 2014;49(9):851\u201361.","journal-title":"Hosp Pharm"},{"issue":"7","key":"1215_CR82","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.xphs.2023.02.006","volume":"112","author":"SM Jakaria","year":"2023","unstructured":"Jakaria SM, Budil DE, Murtagh J. A systematic degradation kinetics study of dalbavancin hydrochloride injection solutions. J Pharm Sci. 2023;112(7):1872\u201387.","journal-title":"J Pharm Sci"},{"issue":"11","key":"1215_CR83","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","volume":"45","author":"M Buckwalter","year":"2005","unstructured":"Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol. 2005;45(11):1279\u201387.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1215_CR84","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ki.2010.35","volume":"77","author":"SJ Vandecasteele","year":"2010","unstructured":"Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 2010;77(9):760\u20134.","journal-title":"Kidney Int"},{"issue":"5","key":"1215_CR85","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/37.5.1017","volume":"37","author":"A Mercatello","year":"1996","unstructured":"Mercatello A, Jaber K, Hillaire-Buys D, Coronel B, Berland J, Despaux E. Concentration of teicoplanin in the serum of adults with end stage chronic renal failure undergoing treatment for infection. J Antimicrob Chemother. 1996;37(5):1017\u201321.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1215_CR86","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","volume":"51","author":"D Andes","year":"2007","unstructured":"Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51(5):1633\u201342.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1215_CR87","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/1440-1681.12195","volume":"41","author":"AH Salem","year":"2014","unstructured":"Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus. Clin Exp Pharmacol Physiol. 2014;41(6):437\u201343.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"12","key":"1215_CR88","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","volume":"59","author":"A Lepak","year":"2015","unstructured":"Lepak A, Marchillo K, VanHecker J, Andes D. Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target. Antimicrob Agents Chemother. 2015;59(12):7833\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1215_CR89","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw274","volume":"4","author":"TP Lodise","year":"2017","unstructured":"Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials. Open Forum Infect Dis. 2017;4(1):ofw274.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"1215_CR90","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1128\/AAC.47.5.1700-1706.2003","volume":"47","author":"CJ Boylan","year":"2003","unstructured":"Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003;47(5):1700\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1215_CR91","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1128\/AAC.49.1.148-152.2005","volume":"49","author":"GJ Fetterly","year":"2005","unstructured":"Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3\u00a0days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005;49(1):148\u201352.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1215_CR92","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1128\/AAC.00176-15","volume":"59","author":"CM Rubino","year":"2015","unstructured":"Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase\u00a03 clinical trials. Antimicrob Agents Chemother. 2015;59(6):3365\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"1215_CR93","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s40265-015-0478-7","volume":"75","author":"YY Syed","year":"2015","unstructured":"Syed YY, Scott LJ. Oritavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(16):1891\u2013902.","journal-title":"Drugs"},{"key":"1215_CR94","unstructured":"FDA. Oritavancin: FDA label. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206334s000lbl.pdf. Accessed 17 Apr 2025."},{"issue":"1","key":"1215_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-016-0103-4","volume":"5","author":"KD Brade","year":"2016","unstructured":"Brade KD, Rybak JM, Rybak MJ. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections. Infect Dis Ther. 2016;5(1):1\u201315.","journal-title":"Infect Dis Ther"},{"key":"1215_CR96","unstructured":"Forrest A, Prakhya A, Rubino C, et al. Pharmacokinetics-pharmacodynamics (PK-PD) of oritavancin (ORI) efficacy in patients with complicated skin and skin structure infections (cSSSI). Infectious Diseases Society of America (IDSA) 46th Annual Meeting; October 25\u201328, 2008; Washington, DC."},{"issue":"10","key":"1215_CR97","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","volume":"41","author":"LE Jauregui","year":"2005","unstructured":"Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41(10):1407\u201315.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1215_CR98","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1185\/03007995.2010.481251","volume":"26","author":"JF Logman","year":"2010","unstructured":"Logman JF, Stephens J, Heeg B, et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin. 2010;26(7):1565\u201378.","journal-title":"Curr Med Res Opin"},{"key":"1215_CR99","unstructured":"Puttagunta S, Boucher H, Talbot GH, Dunne M. Efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in patients meeting SIRS criteria at baseline. Cortellis. 2014. https:\/\/www.cortellis.com\/intelligence\/report\/ci\/sourcesConferenceDocument\/1590869. Accessed 17 Apr 2025."},{"key":"1215_CR100","unstructured":"Dunne M, Puttagunta S. Dalbavancin for the treatment of complicated skin and soft tissue infections in patients with and without diabetes mellitus in the DISCOVER studies. Cortellis.2014. https:\/\/www.cortellis.com\/intelligence\/report\/ci\/sourcesConferenceDocument\/1553667. Accessed 17 Apr 2025."},{"issue":"2","key":"1215_CR101","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.ijid.2010.10.003","volume":"15","author":"BA Lipsky","year":"2011","unstructured":"Lipsky BA, Itani KMF, Weigelt JA, et al. The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. Int J Infect Dis. 2011;15(2):e140\u20136.","journal-title":"Int J Infect Dis"},{"key":"1215_CR102","doi-asserted-by":"crossref","unstructured":"Mart\u00ed-Carvajal AJ, Dayer M, Conterno LO, Gonzalez Garay AG, Mart\u00ed-Amarista CE. A comparison of different antibiotic regimens for the treatment of infective endocarditis. Cochrane Database Syst Rev. 2020;5(5):CD009880.","DOI":"10.1002\/14651858.CD009880.pub3"},{"issue":"7","key":"1215_CR103","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","volume":"36","author":"D Gonzalez","year":"2017","unstructured":"Gonzalez D, Bradley JS, Blumer J, et al. Dalbavancin pharmacokinetics and safety in children 3\u00a0months to 11\u00a0years of age. Pediatr Infect Dis J. 2017;36(7):645\u201353.","journal-title":"Pediatr Infect Dis J"},{"key":"1215_CR104","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001538","author":"D Gonzalez","year":"2017","unstructured":"Gonzalez D, Bradley JS, Blumer J, et al. Dalbavancin pharmacokinetics and safety in children 3\u00a0months to 11\u00a0years of age. Pediatr Infect Dis J. 2017. https:\/\/doi.org\/10.1097\/INF.0000000000001538.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"1215_CR105","first-page":"208","volume":"13","author":"N Jagan","year":"2018","unstructured":"Jagan N, Pendru R, Jyothinath K. Efficacy of dalbavancin and telavancin in the treatment of acute bacterial skin and skin structure infections. Maedica (Buchar). 2018;13(3):208\u201312.","journal-title":"Maedica (Buchar)"},{"key":"1215_CR106","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgar.2019.02.007","volume":"17","author":"U Rappo","year":"2019","unstructured":"Rappo U, Gonzalez PL, Puttagunta S, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019;17:60\u20135.","journal-title":"J Glob Antimicrob Resist"},{"key":"1215_CR107","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae186","author":"S Zambrano","year":"2024","unstructured":"Zambrano S, Paras ML, Suzuki J, et al. Real-world dalbavancin use for serious Gram-positive infections: comparing outcomes between people who use and do not use drugs. Open Forum Infect Dis. 2024. https:\/\/doi.org\/10.1093\/ofid\/ofae186.","journal-title":"Open Forum Infect Dis"},{"key":"1215_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071205","author":"P Ioannou","year":"2023","unstructured":"Ioannou P, Wolff N, Mathioudaki A, Spanias C, Spernovasilis N, Kofteridis DP. Real-world data regarding dalbavancin use before and during the COVID-19 pandemic-a single-center retrospective study. Antibiotics. 2023. https:\/\/doi.org\/10.3390\/antibiotics12071205.","journal-title":"Antibiotics"},{"issue":"10","key":"1215_CR109","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbamem.2010.06.011","volume":"1798","author":"O Domenech","year":"2010","unstructured":"Domenech O, Dufr\u00eane YF, Van Bambeke F, Tukens PM, Mingeot-Leclercq M-P. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochim Biophys Acta. 2010;1798(10):1876\u201385.","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"1215_CR110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s40801-020-00201-y","volume":"7","author":"B Helton","year":"2020","unstructured":"Helton B, MacWhinnie A, Minor SB, Lodise TP, Rafferty KD, Allison SL. Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis. Drugs Real World Outcomes. 2020;7(Suppl 1):20\u20139.","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"1215_CR111","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s40801-020-00189-5","volume":"7","author":"M Redell","year":"2020","unstructured":"Redell M. Real-world evidence studies of oritavancin use in gram-positive infections augment randomized controlled trials to address clinical and economic outcomes. Drugs Real World Outcomes. 2020;7(1):2\u20135.","journal-title":"Drugs Real World Outcomes"},{"issue":"Suppl 1","key":"1215_CR112","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40801-020-00196-6","volume":"7","author":"C Whittaker","year":"2020","unstructured":"Whittaker C, Lodise TP, Nhan E, Reilly J. Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway. Drugs Real World Outcomes. 2020;7(Suppl 1):30\u20135.","journal-title":"Drugs Real World Outcomes"},{"issue":"Suppl 1","key":"1215_CR113","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s40801-020-00201-y","volume":"7","author":"B Helton","year":"2020","unstructured":"Helton B, MacWhinnie A, Minor SB, Lodise TP, Rafferty KD, Allison SL. Early directed oritavancin therapy in the emergency department may lead to hospital avoidance compared to standard treatment for acute bacterial skin and skin structure infections: a real-world retrospective analysis. Drugs Real World Outcomes. 2020;7(Suppl 1):20\u20139.","journal-title":"Drugs Real World Outcomes"},{"issue":"Suppl 1","key":"1215_CR114","first-page":"36","volume":"7","author":"WE Rose","year":"2020","unstructured":"Rose WE, Hutson PR. A two-dose oritavancin regimen using pharmacokinetic estimation analysis. Drugs. 2020;7(Suppl 1):36\u201340.","journal-title":"Drugs"},{"issue":"1","key":"1215_CR115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-016-0145-7","volume":"6","author":"PJ Anastasio","year":"2017","unstructured":"Anastasio PJ, Wolthoff P, Galli A, Fan W. Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study. Infect Dis Ther. 2017;6(1):115\u201328.","journal-title":"Infect Dis Ther"},{"key":"1215_CR116","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40801-020-00192-w","volume":"7","author":"LE Brownell","year":"2020","unstructured":"Brownell LE, Adamsick ML, McCreary EK, et al. Clinical outcomes and economic impact of oritavancin for gram-positive infections: a single academic medical center health system experience. Drugs-Real World Outcomes. 2020;7:13\u20139.","journal-title":"Drugs-Real World Outcomes"},{"issue":"Suppl 1","key":"1215_CR117","first-page":"46","volume":"7","author":"PJ Scoble","year":"2020","unstructured":"Scoble PJ, Reilly J, Tillotson GS. Real-world use of oritavancin for the treatment of osteomyelitis. Drugs. 2020;7(Suppl 1):46\u201354.","journal-title":"Drugs"},{"key":"1215_CR118","doi-asserted-by":"crossref","unstructured":"Bradley J, Arrieta A, Bokesch P, Fusaro K, Griffith DC, Loutit JS. 1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial. Open Forum Infect Dis. 2018;5(suppl_1):S52-S.","DOI":"10.1093\/ofid\/ofy209.125"},{"issue":"1","key":"1215_CR119","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy331","volume":"6","author":"U Rappo","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;6(1):ofy331.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1215_CR120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","volume":"93","author":"TA Almangour","year":"2019","unstructured":"Almangour TA, Perry GK, Terriff CM, Alhifany AA, Kaye KS. Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility. Diagn Microbiol Infect Dis. 2019;93(3):213\u20138.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1215_CR121","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02280-18","author":"L Morata","year":"2019","unstructured":"Morata L, Cobo J, Fernandez-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.02280-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1215_CR122","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-019-01354-x","author":"S Tobudic","year":"2019","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019. https:\/\/doi.org\/10.1007\/s15010-019-01354-x.","journal-title":"Infection"},{"issue":"Suppl 1","key":"1215_CR123","first-page":"41","volume":"7","author":"NW Van Hise","year":"2020","unstructured":"Van Hise NW, Chundi V, Didwania V, et al. Treatment of acute osteomyelitis with once-weekly oritavancin: a two-year, multicenter, retrospective study. Drugs. 2020;7(Suppl 1):41\u20135.","journal-title":"Drugs"},{"issue":"2","key":"1215_CR124","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1871526517666161108130148","volume":"17","author":"SJ Antony","year":"2017","unstructured":"Antony SJ, Cooper LG. Use of oritavancin (novel new lipoglycopeptide) in the treatment of prosthetic joint infections (PJI): a possible alternative novel approach to a difficult problem. Infect Disord Drug Targets. 2017;17(2):77\u201380.","journal-title":"Infect Disord Drug Targets"},{"key":"1215_CR125","first-page":"1","volume":"26","author":"R Foster","year":"2017","unstructured":"Foster R, Philavong K, Weissman S, Tang X, Bookstaver B. Oritavancin for the treatment of daptomycin nonsusceptible vancomycin-resistant enterococci osteomyelitis. Infect Dis Clin Pract. 2017;26:1.","journal-title":"Infect Dis Clin Pract"},{"issue":"3","key":"1215_CR126","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","volume":"40","author":"I Raad","year":"2005","unstructured":"Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374\u201380.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1215_CR127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diagmicrobio.2005.09.004","volume":"54","author":"BP Goldstein","year":"2006","unstructured":"Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diagn Microbiol Infect Dis. 2006;54(2):83\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"1215_CR128","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/jac\/dkz006","volume":"74","author":"HS Sader","year":"2019","unstructured":"Sader HS, Mendes RE, Pfaller MA, Flamm RK. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. J Antimicrob Chemother. 2019;74(5):1306\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1215_CR129","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","volume":"18","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Vinuesa D, Plata A, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019;18(1):30.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"1215_CR130","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67(5):795\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1215_CR131","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06370-1","volume":"23","author":"NA Turner","year":"2022","unstructured":"Turner NA, Zaharoff S, King H, et al. Dalbavancin as an option for treatment of S.\u00a0aureus bacteremia (DOTS): study protocol for a phase\u00a02b, multicenter, randomized, open-label clinical trial. Trials. 2022;23(1): 407.","journal-title":"Trials"},{"key":"1215_CR132","unstructured":"Melinta Therapeutics. A study to evaluate the safety and efficacy of oritavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric subjects. 2017. https:\/\/clinicaltrials.gov\/study\/NCT03148756. Accessed 17 Apr 2025."},{"issue":"1","key":"1215_CR133","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/antibiotics13010020","volume":"13","author":"D Cattaneo","year":"2024","unstructured":"Cattaneo D, Fusi M, Colaneri M, et al. Therapeutic drug monitoring of dalbavancin in real life: a two-year experience. Antibiotics. 2024;13(1):20.","journal-title":"Antibiotics"},{"issue":"4","key":"1215_CR134","doi-asserted-by":"crossref","first-page":"e00023","DOI":"10.1128\/aac.00023-24","volume":"68","author":"D Cattaneo","year":"2024","unstructured":"Cattaneo D, Fusi M, Galli L, et al. Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular\/periprosthetic joint infections. Antimicrob Agents Chemother. 2024;68(4):e00023-24.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"1215_CR135","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/jac\/dkaf132","volume":"80","author":"D Cattaneo","year":"2025","unstructured":"Cattaneo D, Fusi M, Mariani C, et al. Effect of body mass index on the timing of therapeutic drug monitoring-guided dalbavancin dosing in patients with osteoarticular infections. J Antimicrob Chemother. 2025;80(6):1726\u201332.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"1215_CR136","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","volume":"39","author":"MW Dunne","year":"2016","unstructured":"Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S. Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf. 2016;39(2):147\u201357.","journal-title":"Drug Saf"},{"key":"1215_CR137","unstructured":"FDA. Dalbavancin label. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021883s007lbl.pdf. Accessed 17 Apr 2025."},{"issue":"2","key":"1215_CR138","doi-asserted-by":"crossref","first-page":"182.e1","DOI":"10.1016\/j.amjmed.2009.05.031","volume":"123","author":"KA Hazlewood","year":"2010","unstructured":"Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123(2):182.e1-7.","journal-title":"Am J Med"},{"issue":"3","key":"1215_CR139","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","volume":"102","author":"EJ Filippone","year":"2017","unstructured":"Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017;102(3):459\u201369.","journal-title":"Clin Pharmacol Ther"},{"key":"1215_CR140","doi-asserted-by":"crossref","unstructured":"Campbell KC, Kelly E, Targovnik N, et al. Audiologic monitoring for potential ototoxicity in a phase\u00a0I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol. 2003;14(3):157\u201368; quiz 70\u20131.","DOI":"10.1055\/s-0040-1715720"},{"issue":"7","key":"1215_CR141","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1177\/0091270004266620","volume":"44","author":"S Barriere","year":"2004","unstructured":"Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004;44(7):689\u201395.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1215_CR142","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijantimicag.2014.12.021","volume":"45","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45(4):393\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"1215_CR143","first-page":"189","volume":"8","author":"S Mitra","year":"2015","unstructured":"Mitra S, Saeed U, Havlichek DH, Stein GE. Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections. Infect Drug Resist. 2015;8:189\u201397.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"1215_CR144","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","volume":"60","author":"GR Corey","year":"2015","unstructured":"Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7\u201310\u00a0days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254\u201362.","journal-title":"Clin Infect Dis"},{"key":"1215_CR145","doi-asserted-by":"crossref","unstructured":"Shaju AM, Panicker N, Chandni V, Lakshmi Prasanna VM, Nair G, Subeesh V. Drugs-associated with red man syndrome: an integrative approach using disproportionality analysis and Pharmip. J Clin Pharm Ther. 2022;47(10):1650\u20138.","DOI":"10.1111\/jcpt.13716"},{"key":"1215_CR146","unstructured":"Melinta Therapeutics. Pharmacokinetics and safety of oritavancin in pediatric subjects with suspected or confirmed Gram-positive infections. ClinicalTrials.gov; 2014. https:\/\/clinicaltrials.gov\/study\/NCT02134301. Accessed 17 Apr 2025."},{"key":"1215_CR147","unstructured":"Melinta Therapeutics. Dalbavancin in children with acute bacterial skin and skin structure infections (ABSSSI). ClinicalTrials.gov; 2024. https:\/\/clinicaltrials.gov\/study\/NCT06810583. Accessed 17 Apr 2025."},{"issue":"2","key":"1215_CR148","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/antibiotics7020030","volume":"7","author":"R Alduina","year":"2018","unstructured":"Alduina R, Sosio M, Donadio S. Complex regulatory networks governing production of the glycopeptide A40926. Antibiotics. 2018;7(2):30. https:\/\/doi.org\/10.3390\/antibiotics7020030.","journal-title":"Antibiotics"},{"key":"1215_CR149","unstructured":"FDA. Orbactiv (oritavancin) prescribing information: U.S. Food and Drug Administration. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206334s000lbl.pdf."},{"key":"1215_CR150","unstructured":"FDA. Dalvance (dalbavancin) prescribing information: U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021883s005lbl.pdf. Accessed 17 Apr 2025."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01215-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01215-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01215-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:27:30Z","timestamp":1759138050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01215-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":150,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01215-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jian Li is an Australian National Health and Medical Research Council (NHMRC) Principal Research Fellow, and Tony Velkov is an Australian Research Council Mid-Career Industry Fellow. All other authors (Maytham Hussein, James Barclay, Mark Baker, Yuezhou Wu, Varsha J. Thombare, Nitin Patil, Ananya B. Murthy, Rajnikant Sharma, Gauri G. Rao, and Mark A. T. Blaskovich) declare no conflicting interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}